A SEK 20m to SEK 35m financing based with the financial partner Formue Nord Fokus A/S eases the fina...
Carasent has entered into an agreement to sell the Confrere brand and customer contracts to Compodiu...
Having already achieved proof-of-performance for its proprietary digital technique for detection of ...
Vitrolife’s Q4 delivers a high 56.9% gross margins despite a quarter with an unfavorable Technology ...
Redeye updates its estimates and valuation following Lifco’s Q4 2023 report.
Redeye returns with an update following Hoylu’s Q4 2023 report that missed our expectations across t...
Ferronordic will report its Q4 2023 results on 22 February.
Redeye has updated its estimates and valuation following Kontigo Care’s Q4’23 report.
5.2% organic sales growth, improving margins EBITDA up 1.
Redeye highlights two positive developments for Acarix: a SEK33.
Redeye shares its preview of Sedana Medical’s Q4 2023e results, due February 15.
Bishopsgate looks highly complementary, ... ...provides diversification, and is accretive We are opt...
Market-leading white-label software provider for takeaway restaurants 13% ARR CAGR and 11pp EBITDA m...
Q4e: first quarter since Q4'21 with positive y-o-y EBITA growth Gradual margin improvement expected ...
DT’s Q4 results topped estimates as costs remained under control while SBU continued to drive growth...
Redeye’s first comments follow this morning’s Q4 report from Tagmaster.
SRV’s current low risk backlog will support it through the tougher market with hopes for higher marg...
Redeye will likely increase its Base Case and forecasts slightly following a Q4 report coming in som...
Sales and EBITDA inline with pre-announcement 31% organic growth in Technology Estimates likely up 1...
As a result of the earlier trading update, the main interest is in the outlook, especially for the U...
